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hosphorylation and ubiquitination 
get most of the attention, but 
plenty of other posttranslational 
modifi   cations abound. New Rockefeller 
University assistant professor Howard Hang 
believes scientists may be overlooking many 
of these important decorations because they 
lack the means to 
identify them.
As a graduate 
student, Hang was 
fascinated by carbo-
hydrate moieties 
called glycans and 
the vast array of pos-
sibilities they offer. 
When stuck onto sur-
face proteins, these 
sugar groups can 
form slippery, protec-
tive cellular barriers. Glycans can also 
stabilize a protein, change its cellular desti-
nation, or alter its interaction partners (1).
Most glycosyltransferases lack conve-
nient consensus target sequences, so Hang 
sought approaches to identify their sub-
strates. He found small molecule inhibi-
tors for specifi  c glycosyltransferases (2) 
and synthesized identifi  able sugar tags 
(3, 4). After extending his methods to lip-
id modifi  cations (5), Hang is now poised 
to look towards the biology. He believes 
that human pathogens attempt to outwit 
their targets—our cells—by manipulating 
posttranslational modifi  cation pathways.
CALIFORNIA DREAMING
What got you interested in science?
I actually liked organic chemistry in 
college (at UC Santa Cruz). That was the 
fi  rst time science really made sense to 
me, mostly because it involved learning 
some basic principles that allowed you to 
build more complex molecules. I liked 
learning the rules of molecules’ interact-
ing with each other rather than remem-
bering what they are. And then it evolved 
from building molecules to applying 
them to understanding biology.
So you focused on organic chemistry 
for your Ph.D. at UC Berkeley?
Yes. I did my Ph.D. with Carolyn Bertozzi. 
She’s a very creative chemist who is most-
ly geared towards developing tools to un-
derstand glycobiology. In her lab, I learned 
about synthesizing organic molecules and 
asking biological questions with them.
Much like kinases, there are several iso-
forms of glycosyltransferases with similar 
catalytic activity but most likely with dis-
crete functions. There were really no tools 
at the time to evaluate their functions with 
small molecules. The hope was that we 
would fi  nd selective inhibitors of each of 
the isoforms that add each individual carbo-
hydrate onto a growing lipid or protein.
We also tried to develop methods to 
identify the proteins that carry specifi  c 
types of modifi  cations. Just like for kinases 
or the ubiquitin fi  eld, we asked what pro-
teins were modifi  ed with specifi  c glycans.
How did this work drive your scientiﬁ  c 
career path?
Over the last few years, I’ve been gener-
ally interested in how posttranslational 
events affect protein function. But for 
many modifi  cations, we don’t have very 
good detection methods to identify which 
proteins are modifi  ed.
Why do you think that’s been so difﬁ  cult?
The problem with these modifi  cations is 
that they’re transient and heterogeneous. 
They’re often at substoichiometric levels. 
They come on and off at different cellular 
states. So, abundance is naturally an issue.
Heterogeneity is the other problem. It’s 
not like one modifi  cation is on one protein. 
A given protein can have fi  ve of the same 
modifi   cations on different sites. So that 
makes things kind of complicated.
What are the biggest problems you’ve 
encountered?
Historically, all modifi   cations have been 
detected by radioactivity: radioactive ATP, 
or nucleotide sugars, or fatty acids. The 
problem is, if you 
want to identify a pro-
tein selectively that 
carries those modifi  -
cations, there’s no 
intrinsic way to do 
affi   nity retrieval of 
radioactively labeled 
proteins. And often, 
radioactivity is—while 
effective—a bit cumbersome and slow.
Even for modifi  cations which we have 
antibodies to detect selectivity, like phos-
phorylation of histones, for example, they 
are often context specifi  c. I think the only 
antibody that’s specifi  c for a posttransla-
tional modifi  cation is phosphotyrosine, and 
that’s a rare exception that’s very general.
So part of my interest is in developing 
general chemical tools for looking at 
different types of modifi  cations. We start-
ed with glycosylation, and I ventured into 
protein lipidation, which we’re continuing 
to work on.
EAST COAST HIP
That interest in protein lipidation was 
piqued by your postdoctoral work in 
Hidde Ploegh’s lab at MIT. How did you 
choose his lab?
That came from the fact that I got inter-
ested in host–pathogen interactions. I 
liked the idea of how viruses and bacteria 
are able to evade the immune response, 
how over years of evolution, two organ-
isms coevolved to coexist.
It always seemed to me that nature 
was much more clever than scientists at 
manipulating cell biology. And studying 
that would actually give you some key 
insight into how cell biology worked.
And how is that linked to 
posttranslational modiﬁ  cations?
Since we don’t have very many tools to 
study posttranslational modifi  cations, it’s 
hard to analyze all the cellular effects of 
an infection. So we often find things 
that bacteria or viruses do to modulate 
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phosphorylation or cytoskeletal rearrange-
ments, just because we have good meth-
ods to analyze those pathways.
What sort of tools have you developed 
to look at other modiﬁ  cations, and how 
do they work?
We’ve developed reagents for glyco-
sylation and lipidation, and we’re starting 
to think about other types of posttransla-
tional modifi  cations.
We take chemically reactive functional 
groups and install them onto the substrates 
that would be used by enzymes that add 
the modifi  cations. For example, for the 
lipid work, we modifi  ed fatty acids with 
a chemical reporter, such as an azide or 
an alkyne group.
Then we take advantage of the fact that 
those two groups have some unique chemi-
cal properties that we can use to convert 
them into a fl  uorescent 
tag or an affi  nity handle. 
We essentially install 
on small molecules, like 
metabolites, the same 
thing people do for pro-
teins. But instead of 
putting on an HA tag, 
we put a small chemical 
reporter that allows us 
to see them selectively.
The hope is that the 
derivitized substrates 
will be used by the 
cell’s enzymes, which then gives us a 
signal to follow that’s more robust than 
radioactivity. And it gives us the opportu-
nity to enrich for things that are modifi  ed.
How will you now apply these tools to 
biology in your new lab at Rockefeller?
Many pathogens—particularly bacteria—
inject enzymes directly into the host cell 
that modulate signaling pathways, which 
we have very little data on. Now that we 
have better methods to look at posttrans-
lational modifi  cations, we can ask, in the 
presence of these enzymes, are these path-
ways perturbed?
And we don’t have to go in totally blind. 
For some, we match the chemical tool with 
the proposed enzymatic activity of a 
bacterial enzyme or toxin based on bio-
informatics analysis. For example, there’s 
a family of phospholipases from several 
gram-negative bacteria that we don’t have 
substrates for. Now that we have tools to 
look at lipidated proteins, we can ask, are 
there potential substrates of the phospho-
lipases that are lipidated proteins?
Have you had much experience in the 
biology of infectious disease?
In Hidde’s lab I got interested in how intra-
cellular bacteria like Salmonella avoid 
degradation by proteases in mammalian 
cells.  We showed that active proteases 
were excluded from Salmonella-containing 
vacuoles (6). This might be one way bugs 
manage to survive in host cells.
Another goal of your lab is to identify 
antigens that are involved in immune 
responses?
When we get infected with or exposed 
to pathogens, we present antigens to the 
immune system, and that educates the 
body on what we’ve been exposed to. This 
essentially vaccinates us against a second 
round of infection.
For many bacterial pathogens, we 
don’t know what the antigens are at the 
molecular level. This makes it difficult 
to design effective vaccines. So we are 
trying to directly purify the antigens from 
infected cells and characterize them by 
mass spectrometry.
What’s the long-term goal from that?
One goal is to identify antigens that are 
presented to the immune system at dif-
ferent stages of infection, so that you 
can then identify antigen-specifi  c immune 
responses in mouse models.
The corollary to that is, once we 
identify new antigens, they’re potential 
vaccine candidates. You could test whether 
these specifi  c antigens might be more 
effective versus what we already use, 
which are attenuated strains of bacteria 
for which we don’t know the antigens. 
Hopefully, it will be a more precise 
method of designing vaccines.
IF HE CAN MAKE IT THERE...
You arrived at Rockefeller University 
in February of this year. How are you 
liking it?
It’s a great place to start. I think the big 
advantage is the freedom of this place. 
The small but very diverse community 
encourages me to ask questions about 
general problems that we don’t under-
stand. It gives me the freedom to try 
different methods and approaches. I don’t 
feel constrained, based on whether I 
should be a chemist, or a biologist, or 
whatever. Here, I can just ask scientifi  c 
questions and not worry about whether 
my department chair is into that or not.
So you interact with many colleagues 
who have different areas of expertise?
Definitely, just within the small cam-
pus itself—from immunologists, to 
neuroscientists, to other chemical biol-
ogy people. Rockefeller also has a very 
rich tradition in bacterial pathogenesis. 
I think it was ideal for me, from a 
scientifi  c point of view. And from a per-
sonal point of view, I enjoy New York 
City as well.
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Fatty-acylated proteins can be detected in cells 
via metabolic labeling with azido-fatty acids.
“It always 
seemed to 
me that 
nature was 
much more 
clever than 
scientists at 
manipulating 
cell biology.”
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